WuXi Biologics (Cayman) Inc. Stock OTC Markets

Equities

WXXWY

US98260N1081

Biotechnology & Medical Research

Market Closed - OTC Markets 15:54:04 2024-05-30 EDT 5-day change 1st Jan Change
2.846 USD -1.19% Intraday chart for WuXi Biologics (Cayman) Inc. -10.74% -61.80%

Financials

Sales 2024 * 18.14B 2.5B 3.42B Sales 2025 * 21.59B 2.98B 4.07B Capitalization 43.14B 5.96B 8.13B
Net income 2024 * 3.85B 532M 726M Net income 2025 * 4.87B 672M 917M EV / Sales 2024 * 1.98 x
Net cash position 2024 * 7.25B 1B 1.37B Net cash position 2025 * 8.19B 1.13B 1.54B EV / Sales 2025 * 1.62 x
P/E ratio 2024 *
11.6 x
P/E ratio 2025 *
9.09 x
Employees 12,740
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.19%
1 week-10.74%
Current month-16.30%
1 month-16.30%
3 months-40.47%
6 months-74.32%
Current year-61.80%
More quotes
1 week
2.83
Extreme 2.83
3.06
1 month
2.83
Extreme 2.83
3.98
Current year
2.83
Extreme 2.83
7.87
1 year
2.83
Extreme 2.83
13.25
3 years
2.83
Extreme 2.83
38.00
5 years
2.83
Extreme 2.83
43.36
10 years
2.83
Extreme 2.83
43.36
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 11-05-31
Director of Finance/CFO 54 21-08-22
Chief Tech/Sci/R&D Officer 57 -
Members of the board TitleAgeSince
Director/Board Member 73 23-05-05
Director/Board Member 75 17-05-16
Chairman 56 10-04-30
More insiders
Date Price Change Volume
24-05-30 2.846 -1.19% 88,813
24-05-29 2.88 -2.24% 113,802
24-05-28 2.946 -6.77% 257,427
24-05-24 3.16 -0.88% 42,127
24-05-23 3.188 -3.74% 110,185

Delayed Quote OTC Markets, May 30, 2024 at 03:54 pm

More quotes
WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
10.38 CNY
Average target price
24.91 CNY
Spread / Average Target
+140.07%
Consensus

Quarterly revenue - Rate of surprise